What EVERY newly diagnosed Prostate Cancer (PCa) patient needs to know! by John E. Holliday, FACMPE
First, ALL Prostate Cancer patients should determine the basic diagnostic realities of their specific disease and understand its relative significance. In my opinion, EVERY newly diagnosed PCa patient needs to gather the following data, to even START your considerations. I would suggest you begin by acquiring the following diagnostic results. (1) What was my last PSA prior to diagnosis? (If available, previous PSA readings with dates are helpful). Either get copies or write them down. (2) What is my complete Gleason SCORE? (Primary Secondary GRADES = Gleason SCORE) ie: (3 3)= 6, (4 3)= 7, etc. (3) What is the clinical STAGE assigned to my Prostate Cancer? (ie: T1c, T2a, T3b, etc.) (4) Obtain a copy of the Pathology Report from the Biopsy, which should be available from your Physician. It can contain helpful information, now and in the future. Keep it for your records! These 4 items, when coupled with your age and ethnicity, will provide the BASIC information necessary to BEGIN to truly understand what the status of your disease is thought to be, at the time of your diagnosis. When embarking on any journey, when trying to determine the route you want to take, you must first determine where you are NOW, and this is that START! Without knowing this basic information, and understanding its relevance, informed decisions cannot be made and the applicable relevance of gathered information remains undetermined. If a man has been diagnosed with early stage disease, as approximately 3 out of 4 men presenting today are, there is usually no urgent reason or necessity, to make a hurried, uninformed decision. If you feel rushed, pressured or remain uncertain as to whether you know enough to feel relatively comfortable with your choice, wait until you are. Obviously, however, there is no reason to unnecessarily prolong the decision making process beyond that reasonable time frame needed to acquire, and to understand, such information. Delays should NOT be the result of unwarranted procrastination. With this basic information, the educational learning process can begin and more INFORMED decisions are then possible. I will be happy to answer specific questions that anyone may have. - John@newPCa.org (aka) az4peaksView Thread
Hi Francie, - Although you can't significantly help your husband until he is willing to share his feelings and to accept yours, Prostate Cancer (PCa) is a "couples" disease and can also effect you and your marital relationship.
You have been given some suggestions that can be helpful, IF he allows them to be executed. Both you and he can use guidance, as do all newly diagnosed patients and their loved ones. The problem is that you nor he yet know enough to make solid judgments about the veracity of the varying statements that you will read on sites, such as this.
Begin by reading the following article and use it as a starting point for systematically learning about the disease in a more organized fashion. I will help in any way possible and would be happy to talk with you and/or your husband, if he is willing. I,m not new at this, I have been studying, educating and counseling people about PCa for over 13 years. Due to length limitations imposed by WebMD, I will need to Post the forementioned article separately, in the following Post titled:
What EVERY newly diagnosed Prostate Cancer (PCa) patient needs to know! - - I hope you find it helpful! - John@newPCa.org (aka) az4peaksView Thread
Hi Greg - You evidently are being told that you likely have systemic disease, and if this assumption is accurate, you PROBABLY had it at the time of your surgery.
Do you have a printed copy of your post-surgical Pathology report? Its contents should clarify what was found at the time of surgery and provide much more information on which to base your decisions.
From what you have said in your Post, I PRESUME that it shows that there was one or more positive intra-specimen margins or positive surgical margins with extra-capsular extension, however, what is needed is pathological evidence of such possible events.
If you would like help in determining the potential significance of Pathology Report contents, I would be happy to help you make such an assessment, for follow-up with your professional advisors, with whom you can, and should, verify any information acquired here. If interested, feel free to contact me at — John@newPCa.org (aka) az4peaks
Hi Roddy, - NO!!!! Boxer shorts do NOT cause Prostate Cancer (PCa). NO ONE knows the real cause of spontaneous PCa and the thoughts about what does cause it, are largely speculation and hypotheses, without acceptable scientific proof of direct cause and effect. -
There is a small segment of Prostate Cancer patients that are thought to have "inherited" PCa, which infers genetic abnormalities passed directly from one generation to another, but they account for less than 9% of ALL PCa cases.
This is not the same as the familial relationship that provides statistical evidence that increased POTENTIAL susceptibility for PCa occurs in males with first line relatives that have the disease. This does SUGGEST that there is, probably some genetic component in such cases that do acquire the disease, particularly when acquired at earlier ages. - John@newPCa.org (aka) az4peaksView Thread
Hi Fairwind, - This is what happens when a Poster comments on a subject about which he has no knowledge. The question isn't whether this is a "breakthrough" or not, but whether you have any real basis for your original disparaging comments about the contents of the article I posted (without comment).
It had no relationship to Provenge, but when you know nothing about the Poduct involved, it seems unfair and not very pertinent to change the topic to an unrelated product, and to base your derision on information that is totally unassociated with the topic of the original article.
If you want to talk about Provenge's problems, start your OWN thread and don't detract from what was a simple informational based Post!
But, I will let others judge the reliability and veracity of your comments and explanations. I am happy to have them compare our responses and explanations to make such a judgment. - John@newPCa.org (aka) az4peaksView Thread
Hi Fairwind, - I submitted the previous Post, without comment (and with the authors name prominently stated, because I don't personally know whether the contents are accurate or not.
However, after 30 years as a Medical Administrator and 13 years of PCa medical literature research of my own, I am knowledgeable enough to know that the early suspension of an active Medical Study, when accompanied by the offer of the experimental drug and/or treatment to the "patient CONTROL group" (those NOT receiving it) usually indicates that seemingly significant benefits were found to be present in the reported results.
When evidence is considered sufficient, it is considered unethical to NOT take such action. As the story indicates, it is usually an independent monitoring group that makes such a RECOMMENDATION, based upon preliminary results submitted for their review. Those who are actively involved then make the final call, since they are most directly informed and it is their reputations on the line.
Although I have no personal knowledge, other than what is contained in the article, I thought the positive statements it contains (highlighted in this bold print below) warranted its wider distribution to those with advanced Prostate Cancer (PCa), who may be interested in the status of FDA action and the seemingly favorable Study results to date. If so, they can keep track of its further activity.
Your negative and discouraging comments offer NO supportive data to your personal opinions expressed and UNFAIRLY, in my opinion, detract from the hope that it MAY provide for their future.
I will continue to retain my own judgment as to its impact, until more FACTS are known, rather than to depressingly rail at the unknown. - John@newPCa.org (aka) az4peaks
Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field September 26, 2011 By John Carroll
"The experimental prostate cancer drug Alpharadin - - -, with researchers reporting that they had suspended a registration trial after castration-resistant patients taking the alpha radiation drug lived significantly longer with less pain and fewer side effects.
The independent monitoring board called for the early unblinding of the study so that everyone in the study could benefit from the therapy - - -.
Investigators for Algeta and Bayer say that the treatment extended overall survival by 44 percent, with patients living a median average of 14 months compared to 11.2 months in the placebo arm. The treatment also delayed painful bone metastases.
"This appears to be an important study using a highly targeted form of radiation to treat prostate cancer that has spread to the bones," says Professor Gillies McKenna, Cancer Research UK's radiotherapy expert.
Just weeks ago the FDA announced that the agency would put Alpharadin on the regulatory fast track, slashing six months off of the review time - - - -.View Thread
Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field September 26, 2011 — 8:40am ET | By John Carroll
The experimental prostate cancer drug Alpharadin took center stage at the big EMCC meeting in Stockholm, with researchers reporting that they had suspended a registration trial after castration-resistant patients taking the alpha radiation drug lived significantly longer with less pain and fewer side effects. The independent monitoring board called for the early unblinding of the study so that everyone in the study could benefit from the therapy and analysts were quick to dub the treatment a potential game changer in the fast-changing prostate cancer market. Investigators for Algeta and Bayer say that the treatment extended overall survival by 44 percent, with patients living a median average of 14 months compared to 11.2 months in the placebo arm. The treatment also delayed painful bone metastases. Alpha particles can demolish cancer cells far more effectively than standard radiation therapies. Because they have a very narrow target range, down to a few millionth of a meter, it's possible to pinpoint tumors without devastating healthy tissue - significantly easing side effects. "This appears to be an important study using a highly targeted form of radiation to treat prostate cancer that has spread to the bones," says Professor Gillies McKenna, Cancer Research UK's radiotherapy expert. Just weeks ago the FDA announced that the agency would put Alpharadin on the regulatory fast track, slashing six months off of the review time as analysts widely expestpoct a swift approval. The drug is expected to hit peak sales of $1.7 billion on all indications. Bayer signed up for a global development deal on Alpharadin back in 2009. Algeta hung on to an option for up to 50/50 co-promotion and profit-sharing in the USA. TheStreet's Adam Feuerstein, who has been closely following Exelixis 's experimental prostate cancer therapy cabozantinib, astutely notes that the new data on Alpharadin could spell trouble for the rival program. Exelixis wants to mount a pivotal study on endpoints related to pain and bone scan resolution. Regulators, Feuerstein observes, may now insist that the investigators also focus on overall survival--a classic goal in registration studies for cancer drugs--now that Alpharadin has set the bar higher. The new data could also complicate things for Amgen, which is planning to seek an FDA OK to use Xgeva to delay the spread of prostate cancer to the bone without supporting data on added survival times. - see the Bayer release -
Hi to you both, - I have an article, just Posted today on another Website and too lengthy for Posting here, that reasonably addresses the considerations for choosing a Primary treatment.
Although, it does not effectively address the age consideration, in my opinion, it does provide a realively balanced look at varying factors in, treatment considerations.
It is written by an anonymous Urologist. You should find it interesting and, hopefully, helpful. I would be happy to provide an E-mail copy to anyone making a specific request to: John@newPCa.org (aka) az4peaksView Thread